The Week in Review: Nov 30 – Dec 7, 2018

Friday, Dec 7, 2018 News Recap: Renally-Impaired Patients with Chronic Hepatitis B Virus Infection Find Success with Low Dose of TDF A low dose of tenofovir disoproxil fumarate (TDF) may help to preserve renal function and maintain viral suppression in patients with chronic hepatitis B virus infection, even those with advanced liver disease, according to new research. Join Us to Honour & Remember Our Friend Phil Wilkin On Friday December 14,...

Renally-Impaired Patients with Chronic Hepatitis B Virus Infection Find Success with Low Dose of TDF

A low dose of tenofovir disoproxil fumarate (TDF) may help to preserve renal function and maintain viral suppression in patients with chronic hepatitis B virus infection, even those with advanced liver disease, according to new research. TDF (Viread, Gilead) is currently approved for the treatment of chronic hepatitis B virus infection in adults and pediatric patients who are 12 years and older. Although the treatment is effective in inhibiting hepatitis

The Week in Review: Nov 2 – Nov 9, 2018

Friday, Nov 9, 2018 News Recap: Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018 Gilead Sciences announced results from studies investigating Epclusa in chronic HCV patients with severe renal impairment undergoing dialysis and Harvoni in pediatric HCV patients aged three to five years. As well there was data from Gilead’s HBV cure development program. High Prevalence of Cirrhosis in Adults with Chronic...

Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018

SAN FRANCISCO--(BUSINESS WIRE)--Nov 9, 2018--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus (HCV) infected patients with severe renal impairment undergoing dialysis and Harvoni ® (ledipasvir/sofosbuvir) in pediatric HCV patients aged three to five years, adding to the efficacy and safety profile of sofosbuvir-based regimens across diverse pa

High Prevalence of Cirrhosis in Adults With Chronic HBV at a Safety-Net Hospital

Of adults with chronic hepatitis B virus (HBV) infection seen at a safety-net hospital, nearly 30% had cirrhosis at initial presentation, with older male patients being at the highest risk, according to a retrospective study published in the Journal of Clinical and Experimental Hepatology. Cirrhosis is a serious consequence of HBV infection that is associated with a financial burden of $13 billion in the United States. Delays in HBV and cirrhosis diagnosi

The Week in Review: Sep 14 – Sep 21, 2018

Friday, Sep 21, 2018 News Recap: New Chinese HBV Pamphlets from HepCBC There are some new HBV pamphlets from HepCBC in Chinese: HBV Chinese (Traditional) and HBV Chinese (Simplified). View the rest of our new and recently updated pamphlets here: http://hepcbc.ca/publications/pamphlets-posters/ Events: Tuesday, Sept. 25th approximately 11 am - 3 pm is the Downtown Eastside ALLEY Health Fair, location is intersection of Hastings and Columbia S...

The Week in Review: July 27 – August 24, 2018

Friday, August 24, 2018 News Recap: Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...

Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.

Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B virus (HBV)-infection, thus indicating an autoimmune response as possible cause of HCV-infection associated encephalopathy. Data, however, are sparse. This study aims to prove that HCV patients feature sim